-
1
-
-
33845490014
-
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
-
Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-2550.
-
(2006)
N Engl J Med
, vol.355
, pp. 2542-2550
-
-
Sandler, A.1
Gray, R.2
Perry, M.C.3
-
2
-
-
37849052774
-
Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: Analysis of Eastern Cooperative Oncology Group Trial 4599
-
Eastern Cooperative Oncology Group
-
Ramalingam SS, Dahlberg SE, Langer CJ, et al.; Eastern Cooperative Oncology Group. Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599. J Clin Oncol 2008;26:60-65.
-
(2008)
J Clin Oncol
, vol.26
, pp. 60-65
-
-
Ramalingam, S.S.1
Dahlberg, S.E.2
Langer, C.J.3
-
3
-
-
49049089802
-
Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy- naive patients with advanced-stage non-small-cell lung cancer
-
Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy- naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543-3551.
-
(2008)
J Clin Oncol
, vol.26
, pp. 3543-3551
-
-
Scagliotti, G.V.1
Parikh, P.2
Von Pawel, J.3
-
4
-
-
70350225538
-
Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for nonsmall- cell lung cancer: A randomised, double-blind, phase 3 study
-
Ciuleanu T, Brodowicz T, Zielinski C, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for nonsmall- cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009;374:1432-1440.
-
(2009)
Lancet
, vol.374
, pp. 1432-1440
-
-
Ciuleanu, T.1
Brodowicz, T.2
Zielinski, C.3
-
5
-
-
34249843852
-
Survival without common toxicity criteria grade. Toxicity for pemetrexed compared with docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC): A risk-benefit analysis
-
Pujol JL, Paul S, Chouaki N, et al. Survival without common toxicity criteria grade . toxicity for pemetrexed compared with docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC): a risk-benefit analysis. J Thorac Oncol 2007;2:397-401.
-
(2007)
J Thorac Oncol
, vol.2
, pp. 397-401
-
-
Pujol, J.L.1
Paul, S.2
Chouaki, N.3
-
6
-
-
70249116447
-
Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer
-
Patel JD, Hensing TA, Rademaker A, et al. Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer. J Clin Oncol 2009;27:3284-3289.
-
(2009)
J Clin Oncol
, vol.27
, pp. 3284-3289
-
-
Patel, J.D.1
Hensing, T.A.2
Rademaker, A.3
-
7
-
-
77449098773
-
Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced nonsmall- cell lung cancer: NCCTG and SWOG study N0426
-
Adjei AA, Mandrekar SJ, Dy GK, et al. Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced nonsmall- cell lung cancer: NCCTG and SWOG study N0426. J Clin Oncol 2010;28:614-619.
-
(2010)
J Clin Oncol
, vol.28
, pp. 614-619
-
-
Adjei, A.A.1
Mandrekar, S.J.2
Dy, G.K.3
-
8
-
-
84863092492
-
VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: An analysis of data from the AViTA and AVOREN randomised trials
-
Lambrechts D, Claes B, Delmar P, et al. VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials. Lancet Oncol 2012;13:724-733.
-
(2012)
Lancet Oncol
, vol.13
, pp. 724-733
-
-
Lambrechts, D.1
Claes, B.2
Delmar, P.3
-
9
-
-
53749093040
-
Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100
-
ECOG 2100
-
Schneider BP, Wang M, Radovich M, et al.; ECOG 2100. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 2008;26:4672-4678.
-
(2008)
J Clin Oncol
, vol.26
, pp. 4672-4678
-
-
Schneider, B.P.1
Wang, M.2
Radovich, M.3
-
10
-
-
84862778659
-
Polymorphisms of the vascular endothelial growth factor gene and severe radiation pneumonitis in non-small cell lung cancer patients treated with definitive radiotherapy
-
Yin M, Liao Z, Yuan X, et al. Polymorphisms of the vascular endothelial growth factor gene and severe radiation pneumonitis in non-small cell lung cancer patients treated with definitive radiotherapy. Cancer Sci 2012;103:945-950.
-
(2012)
Cancer Sci
, vol.103
, pp. 945-950
-
-
Yin, M.1
Liao, Z.2
Yuan, X.3
-
11
-
-
69949111615
-
Genetic variants in angiogenesis pathway associated with clinical outcome in NSCLC patients (pts) treated with bevacizumab in combination with carboplatin and paclitaxel: Subset pharmacogenetic analysis of ECOG 4599
-
abstr8032
-
Zhang W, Dahlberg SE, Yang D, et al. Genetic variants in angiogenesis pathway associated with clinical outcome in NSCLC patients (pts) treated with bevacizumab in combination with carboplatin and paclitaxel: subset pharmacogenetic analysis of ECOG 4599. J Clin Oncol 2009;27:abstr8032.
-
(2009)
J Clin Oncol
, vol.27
-
-
Zhang, W.1
Dahlberg, S.E.2
Yang, D.3
-
12
-
-
84867272757
-
Correlation between thymidylate synthase gene polymorphisms and efficacy of pemetrexed in advanced non-small cell lung cancer
-
Hu Q, Li X, Su C, et al. Correlation between thymidylate synthase gene polymorphisms and efficacy of pemetrexed in advanced non-small cell lung cancer. Exp Ther Med 2012;4:1010-1016.
-
(2012)
Exp Ther Med
, vol.4
, pp. 1010-1016
-
-
Hu, Q.1
Li, X.2
Su, C.3
-
13
-
-
84866173015
-
Pharmacogenetic study of patients with advanced non-small cell lung cancer (NSCLC) treated with second-line pemetrexed or pemetrexed-carboplatin
-
Tiseo M, Giovannetti E, Tibaldi C, et al. Pharmacogenetic study of patients with advanced non-small cell lung cancer (NSCLC) treated with second-line pemetrexed or pemetrexed-carboplatin. Lung Cancer 2012;78:92-99.
-
(2012)
Lung Cancer
, vol.78
, pp. 92-99
-
-
Tiseo, M.1
Giovannetti, E.2
Tibaldi, C.3
-
14
-
-
65349091355
-
Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer
-
Smit EF, Burgers SA, Biesma B, et al. Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer. J Clin Oncol 2009;27:2038-2045.
-
(2009)
J Clin Oncol
, vol.27
, pp. 2038-2045
-
-
Smit, E.F.1
Burgers, S.A.2
Biesma, B.3
-
15
-
-
77956268512
-
Correlation between polymorphisms of the reduced folate carrier gene (SLC19A1) and survival after pemetrexed-based therapy in non-small cell lung cancer: A North Central Cancer Treatment Group-based exploratory study
-
Adjei AA, Salavaggione OE, Mandrekar SJ, et al. Correlation between polymorphisms of the reduced folate carrier gene (SLC19A1) and survival after pemetrexed-based therapy in non-small cell lung cancer: a North Central Cancer Treatment Group-based exploratory study. J Thorac Oncol 2010;5:1346-1353.
-
(2010)
J Thorac Oncol
, vol.5
, pp. 1346-1353
-
-
Adjei, A.A.1
Salavaggione, O.E.2
Mandrekar, S.J.3
-
16
-
-
33845382806
-
Nonparametric estimation for incomplete observations
-
Kaplan E, Meier P. Nonparametric estimation for incomplete observations. J Am Stat Assoc 1958;53:457-481.
-
(1958)
J Am Stat Assoc
, vol.53
, pp. 457-481
-
-
Kaplan, E.1
Meier, P.2
-
17
-
-
1542289011
-
Issues for statisticians in conducting analyses and translating results for quality of life end points in clinical trials
-
Sloan JA, Dueck A. Issues for statisticians in conducting analyses and translating results for quality of life end points in clinical trials. J Biopharm Stat 2004;14:73-96.
-
(2004)
J Biopharm Stat
, vol.14
, pp. 73-96
-
-
Sloan, J.A.1
Dueck, A.2
-
18
-
-
84655163441
-
A randomized phase II trial of pemetrexed/gemcitabine/bevacizumab or pemetrexed/carboplatin/ bevacizumab in the first-line treatment of elderly patients with advanced non-small cell lung cancer
-
Spigel DR, Hainsworth JD, Shipley DL, et al. A randomized phase II trial of pemetrexed/gemcitabine/bevacizumab or pemetrexed/carboplatin/ bevacizumab in the first-line treatment of elderly patients with advanced non-small cell lung cancer. J Thorac Oncol 2012;7:196-202.
-
(2012)
J Thorac Oncol
, vol.7
, pp. 196-202
-
-
Spigel, D.R.1
Hainsworth, J.D.2
Shipley, D.L.3
-
19
-
-
84875889240
-
Pemetrexed and carboplatin, an active option in first-line treatment of elderly patients with advanced non-small cell lung cancer (NSCLC): A phase II trial
-
Gervais R, Robinet G, Clément-Duchêne C, et al. Pemetrexed and carboplatin, an active option in first-line treatment of elderly patients with advanced non-small cell lung cancer (NSCLC): a phase II trial. Lung Cancer 2013;80:185-190.
-
(2013)
Lung Cancer
, vol.80
, pp. 185-190
-
-
Gervais, R.1
Robinet, G.2
Clément-Duchêne, C.3
-
20
-
-
84875612797
-
Dose escalation study of carboplatin- pemetrexed followed by maintenance pemetrexed for elderly patients with advanced nonsquamous nonsmall-cell lung cancer
-
Tamiya A, Tamiya M, Shiroyama T, et al. Dose escalation study of carboplatin- pemetrexed followed by maintenance pemetrexed for elderly patients with advanced nonsquamous nonsmall-cell lung cancer. Ann Oncol 2013;24:980-985.
-
(2013)
Ann Oncol
, vol.24
, pp. 980-985
-
-
Tamiya, A.1
Tamiya, M.2
Shiroyama, T.3
-
21
-
-
84892454962
-
PointBreak: A randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer
-
Patel JD, Socinski MA, Garon EB, et al. PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. J Clin Oncol 2013;31:4349-4357.
-
(2013)
J Clin Oncol
, vol.31
, pp. 4349-4357
-
-
Patel, J.D.1
Socinski, M.A.2
Garon, E.B.3
-
22
-
-
84886384997
-
Efficacy and safety of paclitaxel and carboplatin with bevacizumab for the first-line treatment of patients with nonsquamous non-small cell lung cancer (NSCLC): Analyses based on age in the phase III PointBreak and E4599 trials
-
abstr 8073
-
Langer CJ, Socinski MA, Patel JD, et al. Efficacy and safety of paclitaxel and carboplatin with bevacizumab for the first-line treatment of patients with nonsquamous non-small cell lung cancer (NSCLC): analyses based on age in the phase III PointBreak and E4599 trials. J Clin Oncol 2013;31:abstr 8073.
-
(2013)
J Clin Oncol
, vol.31
-
-
Langer, C.J.1
Socinski, M.A.2
Patel, J.D.3
-
23
-
-
28044463139
-
Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced nonsmall cell lung cancer
-
Zinner RG, Fossella FV, Gladish GW, et al. Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced nonsmall cell lung cancer. Cancer 2005;104:2449-2456.
-
(2005)
Cancer
, vol.104
, pp. 2449-2456
-
-
Zinner, R.G.1
Fossella, F.V.2
Gladish, G.W.3
-
24
-
-
19944426696
-
Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: A multicenter, randomized, phase II trial
-
Scagliotti GV, Kortsik C, Dark GG, et al. Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: a multicenter, randomized, phase II trial. Clin Cancer Res 2005;11(2 Pt 1):690-696.
-
(2005)
Clin Cancer Res
, vol.11
, Issue.2 PART 1
, pp. 690-696
-
-
Scagliotti, G.V.1
Kortsik, C.2
Dark, G.G.3
-
25
-
-
78650434724
-
Randomized, phase II trial of pemetrexed and carboplatin with or without enzastaurin versus docetaxel and carboplatin as first-line treatment of patients with stage IIIB/IV non-small cell lung cancer
-
Socinski MA, Raju RN, Stinchcombe T, et al. Randomized, phase II trial of pemetrexed and carboplatin with or without enzastaurin versus docetaxel and carboplatin as first-line treatment of patients with stage IIIB/IV non-small cell lung cancer. J Thorac Oncol 2010;5:1963-1969.
-
(2010)
J Thorac Oncol
, vol.5
, pp. 1963-1969
-
-
Socinski, M.A.1
Raju, R.N.2
Stinchcombe, T.3
-
26
-
-
80054911223
-
A randomized phase 3 trial comparing pemetrexed/carboplatin and docetaxel/carboplatin as first-line treatment for advanced, nonsquamous non-small cell lung cancer
-
Rodrigues-Pereira J, Kim JH, Magallanes M, et al. A randomized phase 3 trial comparing pemetrexed/carboplatin and docetaxel/carboplatin as first-line treatment for advanced, nonsquamous non-small cell lung cancer. J Thorac Oncol 2011;6:1907-1914.
-
(2011)
J Thorac Oncol
, vol.6
, pp. 1907-1914
-
-
Rodrigues-Pereira, J.1
Kim, J.H.2
Magallanes, M.3
-
27
-
-
84885924300
-
PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer
-
Paz-Ares LG, de Marinis F, Dediu M, et al. PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Clin Oncol 2013;31:2895-2902.
-
(2013)
J Clin Oncol
, vol.31
, pp. 2895-2902
-
-
Paz-Ares, L.G.1
De Marinis, F.2
Dediu, M.3
-
28
-
-
39749096242
-
VEGF polymorphisms and survival in early-stage non-small-cell lung cancer
-
Heist RS, Zhai R, Liu G, et al. VEGF polymorphisms and survival in early-stage non-small-cell lung cancer. J Clin Oncol 2008;26:856-862.
-
(2008)
J Clin Oncol
, vol.26
, pp. 856-862
-
-
Heist, R.S.1
Zhai, R.2
Liu, G.3
-
29
-
-
79958261031
-
Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer
-
Loupakis F, Ruzzo A, Salvatore L, et al. Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer. BMC Cancer 2011;11:247.
-
(2011)
BMC Cancer
, vol.11
, pp. 247
-
-
Loupakis, F.1
Ruzzo, A.2
Salvatore, L.3
-
30
-
-
70349585443
-
Effect of vascular endothelial growth factor polymorphisms on survival in advanced-stage non-small-cell lung cancer
-
Masago K, Fujita S, Kim YH, et al. Effect of vascular endothelial growth factor polymorphisms on survival in advanced-stage non-small-cell lung cancer. Cancer Sci 2009;100:1917-1922.
-
(2009)
Cancer Sci
, vol.100
, pp. 1917-1922
-
-
Masago, K.1
Fujita, S.2
Kim, Y.H.3
-
31
-
-
84859726033
-
VEGFA and VEGFR2 genetic polymorphisms and survival in patients with diffuse large B cell lymphoma
-
Kim MK, Suh C, Chi HS, et al. VEGFA and VEGFR2 genetic polymorphisms and survival in patients with diffuse large B cell lymphoma. Cancer Sci 2012;103:497-503.
-
(2012)
Cancer Sci
, vol.103
, pp. 497-503
-
-
Kim, M.K.1
Suh, C.2
Chi, H.S.3
-
32
-
-
77953968068
-
Clinical relevance of vascular endothelial growth factor (VEGFA) and VEGF receptor (VEGFR2) gene polymorphism on the treatment outcome following imatinib therapy
-
Kim DH, Xu W, Kamel-Reid S, et al. Clinical relevance of vascular endothelial growth factor (VEGFA) and VEGF receptor (VEGFR2) gene polymorphism on the treatment outcome following imatinib therapy. Ann Oncol 2010;21:1179-1188.
-
(2010)
Ann Oncol
, vol.21
, pp. 1179-1188
-
-
Kim, D.H.1
Xu, W.2
Kamel-Reid, S.3
-
33
-
-
77955240423
-
Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib
-
Jain L, Sissung TM, Danesi R, et al. Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib. J Exp Clin Cancer Res 2010;29:95.
-
(2010)
J Exp Clin Cancer Res
, vol.29
, pp. 95
-
-
Jain, L.1
Sissung, T.M.2
Danesi, R.3
-
34
-
-
81255160848
-
Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: A multicentre, observational, prospective study
-
Garcia-Donas J, Esteban E, Leandro-García LJ, et al. Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study. Lancet Oncol 2011;12:1143-1150.
-
(2011)
Lancet Oncol
, vol.12
, pp. 1143-1150
-
-
Garcia-Donas, J.1
Esteban, E.2
Leandro-García, L.J.3
-
35
-
-
67149114893
-
Association of thymidylate synthase variants with 5-fluorouracil cytotoxicity
-
Peters EJ, Kraja AT, Lin SJ, et al. Association of thymidylate synthase variants with 5-fluorouracil cytotoxicity. Pharmacogenet Genomics 2009;19:399-401.
-
(2009)
Pharmacogenet Genomics
, vol.19
, pp. 399-401
-
-
Peters, E.J.1
Kraja, A.T.2
Lin, S.J.3
|